FLT-3 inhibitors (Proacta)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameFLT-3 inhibitors (Proacta)
Drug Alias NameHSMKIs (Proacta)hypoxia-selective multikinase inhibitors (Proacta)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitors
TargetsTyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesThe University Of Auckland
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesProacta Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A